Evidence map›Paper›PMID 39712287›Full record

ArticleInternational journal of cardiology. Congenital heart disease2022

Off-label use of Lifetech KONAR-MF™ ventricular septal defect occluder for large patent ductus arteriosus closure in <6 ​kg infants.

Céline Grunenwald Gronier, Nadir Benbrik, Bénédicte Romefort, Solène Prigent, Quentin Hauet, Alban-Elouen Baruteau

Abstract read
In one paragraph

Article in International journal of cardiology. Congenital heart disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Editor's corner & issue at a glance.International journal of cardiology. Congenital heart disease · 2022
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Céline Grunenwald GronierNantes Université, CHU Nantes, Département médico-chirurgical de cardiologie pédiatrique et congénitale, F-44000 Nantes, France.
Nadir BenbrikNantes Université, CHU Nantes, Département médico-chirurgical de cardiologie pédiatrique et congénitale, F-44000 Nantes, France.
Bénédicte RomefortNantes Université, CHU Nantes, Département médico-chirurgical de cardiologie pédiatrique et congénitale, F-44000 Nantes, France.
Solène PrigentNantes Université, CHU Nantes, Département médico-chirurgical de cardiologie pédiatrique et congénitale, F-44000 Nantes, France.
Quentin HauetNantes Université, CHU Nantes, Département médico-chirurgical de cardiologie pédiatrique et congénitale, F-44000 Nantes, France.
Alban-Elouen BaruteauNantes Université, CHU Nantes, Département médico-chirurgical de cardiologie pédiatrique et congénitale, F-44000 Nantes, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Device PDA closure is increasingly used in smaller patients. Major safety concerns remain when applied to <6 ​kg infants with large PDA and challenging anatomy. We aimed to report our experience with the new Konar-MF™ ventricular septal defect (VSD) occluder for transcatheter closure of large patent ductus arteriosus (PDA) in infants <6 ​kg. Methods: Infants <6 ​kg in whom PDA occlusion was attempted using the Konar-MF™ VSD occluder were analyzed to review procedural characteristics and outcomes. Prospective follow-up was achieved until August 2021. Results: A total of 9 implantations were performed in 7 infants [age: 5.3 ​± ​3.4 (1.7-10.1) months, weight: 4.1 ​± ​0.8 (2.9-5.8) kg]. All PDAs were large and short [minimal ductal diameter: 5.6 ​± ​1.0 (4.5-7.0) mm, ductal length: 4.3 ​± ​0.6 (3.5-5) mm]. Successful device implantation was achieved in all cases without major complication. Early device embolization occurred in 1 case with safe percutaneous device removal. Late percutaneous device retrieval was achieved 5 weeks after implantation because of symptomatic residual shunt. In both cases a second Konar-MF™ VSD occluder was implanted with excellent outcome. Over a median follow-up of 12 (6-25) months, 1 patient died from a device-unrelated cause; all remaining patients are asymptomatic, with complete occlusion and no delayed device-related complication. Conclusions: Transcatheter closure of large PDA using the Konar-MF™ VSD occluder appears to be feasible, effective and safe in <6 ​kg infants. This approach might be an alternative to surgical ligation in carefully selected infants, although that remains to be confirmed by extensive experience and long-term outcomes data.

Indexed as

Congenital heart diseaseMultifunctional occluderPatent ductus arteriosusPulmonary hypertension

Identifiers

PMID39712287
PMCPMC11658058

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.